Pharma Mar
€71.40Change from previous close: +0.92%Absolute change: +€0.65
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 53.1 | 6.0 | -13.4 | 38.3 | 25.7 |
| Depreciation and amortization | 7.7 | 5.7 | 4.7 | 4.9 | 4.6 |
| Capital expenditure | -6.5 | -15.0 | -14.8 | -8.9 | -7.8 |
| Investing cash flow | -60.8 | 1.0 | -43.0 | 10.9 | 18.5 |
| Financing cash flow | -36.5 | -5.4 | -32.1 | -13.4 | -27.4 |
| Dividends paid | -13.9 | -11.4 | -11.7 | -11.8 | -10.9 |
| Share repurchases | -34.1 | -18.6 | -37.9 | -50.2 | -40.7 |
| Debt issued | 1.3 | 15.4 | 7.2 | 1.5 | 5.8 |
| Debt repaid | -2.8 | -6.5 | -6.3 | -10.2 | — |
| Effect of exchange rates | -1.2 | 1.5 | -1.2 | 0.6 | 0.4 |
| Net change in cash | -45.4 | 3.2 | -89.8 | 36.5 | 17.1 |
| Free cash flow | 46.7 | -9.0 | -28.3 | 29.5 | 17.9 |
| Levered free cash flow | 22.9 | -20.2 | -12.6 | 33.1 | 4.8 |